CardiAMP™ Cell Therapy for Heart Failure Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT02438306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
BioCardia, Inc. (from the registry)
Registry
  • NCT NCT02438306
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02438306. Randomized; double masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2025-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CardiAMP™ Cell Therapy for Heart Failure Trial
Condition
Heart Failure, Systolic
Intervention (Biological)
Autologous cell therapy
Intervention (Other)
Sham
Lead sponsor
BioCardia, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02438306
Content hash
deebe89f51f47e656336a6e8c1503c5663eadee7992433b5a78c69e6f909ba67